Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.

Y-Y ShaoB-B ChenD-L OuZ-Z LinC-H HsuM-J WangA-L ChengChiun Hsu

Published in: Alimentary pharmacology & therapeutics (2017)

Lenalidomide exhibited moderate activity as second-line therapy for advanced HCC. Its immunomodulatory effects should be further explored (www.clinicaltrials.gov NCT01545804).

Keyphrases

multiple myeloma
newly diagnosed
stem cell transplantation
high intensity
chronic lymphocytic leukemia
low dose
combination therapy
high dose